Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.44 (
P-glycoprotein
)
13,344
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ZNRD1
, a new zinc ribbon gene, has been previously identified as an upregulated gene in a multidrug-resistant gastric cancer cell line SGC7901/VCR comparing to its parental cell SGC7901 by subtractive hybridization and RT-PCR. The antisense nucleic acid for
ZNRD1
could enhance adriamycin accumulation in SGC7901/VCR cells and sensitize SGC7901/VCR cells to vincristine. The present study aims to explore the role of
ZNRD1
in multidrug resistance in gastric cancer cells. Upregulation of
ZNRD1
protein in SGC7901/VCR cells was confirmed by Western blot and immunocytochmical staining.
ZNRD1
was genetically overexpressed in SGC7901 cells by gene transfection. It was found that overexpression of
ZNRD1
could sensitize SGC7901 cells to
P-glycoprotein
(
P-gp
)-related anticancer drugs (vincristine, adriamycin, etoposide) but not to
P-gp
-nonrelated drugs (5-fluorouracil and cisplatin), which was accompanied with significantly decreased adriamycin accumulation and retention and increased adriamycin releasing in SGC7901 cells. Verapamil, an inhibitor for
P-gp
, could reverse the effects of
ZNRD1
on drug sensitivity and drug accumulation in SGC7901 cells to a great extent. Western blot and Northern blot revealed that overexpression of
ZNRD1
could upregulate
P-gp
at both protein and mRNA levels. Together, these results suggest that overexpression of
ZNRD1
could promote multidrug-resistant phenotype of gastric cancer cells through upregulation of
P-gp
.
...
PMID:Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. 1497 23
